The Efficacy of Vitamin E in the Treatment of Tardive Dyskinesia: A Double-Blind Placebo Controlled Study
DOI:
https://doi.org/10.5915/26-2-16367Keywords:
Vitamin E, Antioxidant therapy, Tardive dyskinesia, Neuroleptic medication, Chronic schizophreniaAbstract
DOI: http://dx.doi.org/10.5915/26-2-16367
Our aim in this study was to investigate the efficacy of vitamin E in the treatment of tardive dyskinesia in a group of chronic schizophrenic patients. Thirty-eight chronic schizophrenic inpatients with tardive dyskinesia were selected for a double-blind trial of Vitamin E versus placebo (Vitamin E: N=18). Tardive dyskinesia was rated by a blind-trained rater using the Abnormal Involuntary Movement Scale (AIMS) at baseline and after treatment. The AIMS scores in the Vitamin E cohort decreased significantly after treatment while the AJMS scores in the placebo cohort were not different after placebo. The results replicate the short-term effectiveness of Vitamin E in the treatment of tardive dyskinesia in a larger group of chronic schizophrenic patients.
References
Jeste DV, Wyatt RJ: Understanding and treating tardive dyskinesia. New York: Euilford Press 1982.
Cohen G. Oxyradical toxicity in catecholamine neurons. Neurotoxicology. 1984;5:77-82.
Mackay AUP, Iverson LL, Rossor M, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry. 1982;39:991-7.
Cadenos E, Ginsberg M, et al. Examination of alphatocopherol antioxidant activity. Biochem J. 1986;723:755-9.
Jackson LV, Przedborski S, Kostic V et al. Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha tocopherol in rat brains. Brain Res Bull. 1991;26(2):251-8.
Oske FA. Vitamin E, a radical defense. N Engl J Med. 1980;303:454-5.
Machlin LJ. Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl. 1989;30:56-68.
Elkashef AM, Ruskin PE, Bacher N, Barrett. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry. 1990;147:505-6.
Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-7.
Guy W (ed). ECDEU Assessment Manual for Psychopharmacology: Publication ADM76-338. Washington, DC: US Department of Health, Education, and Welfare;1976:534-537.
Lohr JB, Cadet JL, Lohr MA, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull. 1988;14:291-6.
Cadet JL, Lohr JB, Jeste DV.: Free radicals and tardive dyskinsia. Trends in Neuroscience. 1986;9:107-8.
Adler LA, Peselow E, Rosenthal M, el al. Vitamin E treatment of tardive dyskinesia. Biol Psychiatry. 1992;31:61 A-2520.
Shriqui CL, Bradwejn J, Annable L, el al. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. A J Psychiatry. 1992; 149:391-3.
Egan MF, Hyde TM, Albers W, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 1992;149:773-7.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
